Guizhou Bailing Unit Gets China Regulator's Nod to Trial Tangning Tongluo Cream

MT Newswires Live

Yesterday

Bailing Yuxiu (Zhuhai) Pharmaceutical, a wholly-owned subsidiary of Guizhou Bailing Group Pharmaceutical (SHE:002424), has received approval from China's National Medical Products Administration to conduct clinical trials of Tangning Tongluo Cream for diabetic foot ulcers, according to a Wednesday filing with the Shenzhen bourse.

Tangning Tongluo is a traditional Chinese medicine drug available in tablet and cream formulations for diabetes-related conditions.

The clinical trial application was approved subject to further refinement of the trial protocol.

In November 2024, the company received NMPA approval to conduct a Phase III clinical trial of Tangning Tongluo tablets for diabetic retinopathy. In October 2025, it received approval to conduct clinical trials of Tangning Tongluo tablets for Type 2 diabetes.

The company said the cream could potentially complement its Tangning Tongluo tablets to form an "oral plus topical" treatment system.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/news/2668959271"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2668959271\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2668959271?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-17 14:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2668959271","market":"fut","top_or_hot":-1,"title":"Guizhou Bailing Unit Gets China Regulator's Nod to Trial Tangning Tongluo Cream","media":"MT Newswires Live","content":"<html><body><p> Bailing Yuxiu (Zhuhai) Pharmaceutical, a wholly-owned subsidiary of <a href=\"https://laohu8.com/S/002424\">Guizhou Bailing</a> Group Pharmaceutical (SHE:002424), has received approval from China's National Medical Products Administration to conduct clinical trials of Tangning Tongluo Cream for diabetic foot ulcers, according to a Wednesday filing with the Shenzhen bourse.</p><p>Tangning Tongluo is a traditional Chinese medicine drug available in tablet and cream formulations for diabetes-related conditions.</p><p>The clinical trial application was approved subject to further refinement of the trial protocol.</p><p>In November 2024, the company received NMPA approval to conduct a Phase III clinical trial of Tangning Tongluo tablets for diabetic retinopathy. In October 2025, it received approval to conduct clinical trials of Tangning Tongluo tablets for Type 2 diabetes.</p><p>The company said the cream could potentially complement its Tangning Tongluo tablets to form an \"oral plus topical\" treatment system.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Guizhou Bailing Unit Gets China Regulator's Nod to Trial Tangning Tongluo Cream</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGuizhou Bailing Unit Gets China Regulator's Nod to Trial Tangning Tongluo Cream\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-17 14:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Bailing Yuxiu (Zhuhai) Pharmaceutical, a wholly-owned subsidiary of <a href=\"https://laohu8.com/S/002424\">Guizhou Bailing</a> Group Pharmaceutical (SHE:002424), has received approval from China's National Medical Products Administration to conduct clinical trials of Tangning Tongluo Cream for diabetic foot ulcers, according to a Wednesday filing with the Shenzhen bourse.</p><p>Tangning Tongluo is a traditional Chinese medicine drug available in tablet and cream formulations for diabetes-related conditions.</p><p>The clinical trial application was approved subject to further refinement of the trial protocol.</p><p>In November 2024, the company received NMPA approval to conduct a Phase III clinical trial of Tangning Tongluo tablets for diabetic retinopathy. In October 2025, it received approval to conduct clinical trials of Tangning Tongluo tablets for Type 2 diabetes.</p><p>The company said the cream could potentially complement its Tangning Tongluo tablets to form an \"oral plus topical\" treatment system.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HYLG","symbol_name":"GLOBAL X HEALTH CARE COVERED CALL & GROWTH ETF","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2668959271","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2668959271","pubTimestamp":1789625847,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Bailing Yuxiu  Pharmaceutical, a wholly-owned subsidiary of Guizhou Bailing Group Pharmaceutical , has received approval from China's National Medical Products Administration to conduct clinical trials of Tangning Tongluo Cream for diabetic foot ulcers, according to a Wednesday filing with the Shenzhen bourse.Tangning Tongluo is a traditional Chinese medicine drug available in tablet and cream formulations for diabetes-related conditions.The clinical trial application was approved subject to further refinement of the trial protocol.In November 2024, the company received NMPA approval to conduct a Phase III clinical trial of Tangning Tongluo tablets for diabetic retinopathy. In October 2025, it received approval to conduct clinical trials of Tangning Tongluo tablets for Type 2 diabetes.The company said the cream could potentially complement its Tangning Tongluo tablets to form an \"oral plus topical\" treatment system.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HYLG":"GLOBAL X HEALTH CARE COVERED CALL & GROWTH ETF","BK0188":"融资融券","MEDX":"HORIZON KINETICS MEDICAL ETF","BK0077":"质押式回购","NVIB":"Direxion NVDA Defined Income Boost ETF","IDNA":"iShares Genomics Immunology and Healthcare ETF","GDOC":"Goldman Sachs Future Health Care Equity ETF","BK0028":"国家队","BK0146":"智慧医疗","002424":"ST百灵","BK0239":"医药制造","BK0183":"MSCI概念"},"translate_title":"贵州百灵单位获得中国监管机构批准试验唐宁通络霜","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GDOC":0.73,"HYLG":0.73,"IDNA":0.73,"NVIB":0.73,"MEDX":0.73,"002424":0.9},"content_text":"Bailing Yuxiu (Zhuhai) Pharmaceutical, a wholly-owned subsidiary of Guizhou Bailing Group Pharmaceutical (SHE:002424), has received approval from China's National Medical Products Administration to conduct clinical trials of Tangning Tongluo Cream for diabetic foot ulcers, according to a Wednesday filing with the Shenzhen bourse.Tangning Tongluo is a traditional Chinese medicine drug available in tablet and cream formulations for diabetes-related conditions.The clinical trial application was approved subject to further refinement of the trial protocol.In November 2024, the company received NMPA approval to conduct a Phase III clinical trial of Tangning Tongluo tablets for diabetic retinopathy. In October 2025, it received approval to conduct clinical trials of Tangning Tongluo tablets for Type 2 diabetes.The company said the cream could potentially complement its Tangning Tongluo tablets to form an \"oral plus topical\" treatment system.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}